Login

Join for Free!
17726 members
Home Forum Dictionary Articles Tutorials Books Directory Share your work
table of contents table of contents

A comprehensive review of published Markov models in depression and identified potential …

Biology Articles » Psychobiology » Can discrete event simulation be of use in modelling major depression? » References

References
- Can discrete event simulation be of use in modelling major depression?


  1. Paykel ES, Brugha T, Fryers T: Size and burden of depressive disorders in Europe.

    Eur Neuropsychopharmacol 2005, 15(4):411-423.

  2. Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study.

    Lancet 1997, 349(9064):1498-1504.

  3. Segal ZV, Pearson JL, Thase ME: Challenges in preventing relapse in major depression. Report of a National Institute of Mental Health Workshop on state of the science of relapse prevention in major depression.

    J Affect Disord 2003, 77(2):97-108.

  4. Drummond M, Jonsson B, Rutten F: The role of economic evaluation in the pricing and reimbursement of medicines.

    Health Policy 1997, 40(3):199-215.

  5. Sonnenberg FA, Beck JR: Markov models in medical decision making: a practical guide.

    Med Decis Making 1993, 13(4):322-338.

  6. Caro JJ: Pharmacoeconomic analyses using discrete event simulation.

    Pharmacoeconomics 2005, 23(4):323-332.

  7. Keller MB, Boland RJ: Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression.

    Biol Psychiatry 1998, 44(5):348-360.

  8. Akerblad AC, Bengtsson F, von Knorring L, Ekselius L: Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study.

    Int Clin Psychopharmacol 2006, 21(2):117-124.

  9. Keller MB: The long-term treatment of depression.

    J Clin Psychiatry 1999, 60(Suppl 17):41-45.

  10. Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT, et al.: Multiple recurrences of major depressive disorder.

    Am J Psychiatry 2000, 157(2):229-233.

  11. Keller MB, Lavori PW, Rice J, Coryell W, Hirschfeld RM: The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: a prospective follow-up.

    Am J Psychiatry 1986, 143(1):24-28.

  12. Olfson M, Marcus SC, Tedeschi M, Wan GJ: Continuity of antidepressant treatment for adults with depression in the United States.

    Am J Psychiatry 2006, 163(1):101-108.

  13. Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K: The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression.

    Arch Gen Psychiatry 1998, 55(12):1128-1132.

  14. Marcus SM, Young EA, Kerber KB, Kornstein S, Farabaugh AH, Mitchell J, et al.: Gender differences in depression: findings from the STAR*D study.

    J Affect Disord 2005, 87(2–3):141-150.

  15. Beck JR, Pauker SG: The Markov process in medical prognosis.

    Med Decis Making 1983, 3(4):419-458.

  16. NICE guidance on Depression: management of depression in primary and secondary care

    2004.

  17. Kennedy SH, Lam RW, Cohen NL, Ravindran AV: Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments.

    Can J Psychiatry 2001, 46(Suppl 1):38S-58S.

  18. Dardennes R, Lafuma A, Fagnani F, Pribil C, Bisserbe JC, Berdeaux G: Economic Assessment of a Maintenance Treatment Strategy in Prevention of Recurrent Depressive Disorder.

    Value in Health 2000, 3(1):40-47.

  19. Hatziandreu EJ, Brown RE, Revicki DA, Turner R, Martindale J, Levine S, et al.: Cost-Utility of Maintenance Treatment of Recurrent Depression with Sertraline Versus Episodic Treatment with Dothiepin.

    Pharmacoeconomics 1994, 5(3):249-264.

  20. Kamlet MS, Paul N, Greenhouse J, Kupfer D, Frank E, Wade M: Cost-Utility Analysis of Maintenance Treatment for Recurrent Depression.

    Controlled Clinical Trials 1995, 16(1):17-40.

  21. Lafuma A, Dardennes R, Fagnani F, Pribil C, Bisserbe JC, Berdeaux G: Economic assessment of maintenance treatment of recurrent depressive disorder with milnacipran versus episode treatment.

    Encephale-Revue de Psychiatrie Clinique Biologique et Therapeutique 1999, 25(5):401-407.

  22. Nuijten M, Hardens M, Souetre E: A Markov Process Analysis Comparing the Cost-Effectiveness of Maintenance Therapy with Citalopram Versus Standard Therapy in Major Depression.

    Pharmacoeconomics 1995, 8(2):159-168.

  23. Nuijten M, Hadjadjeba L, Evans C, van den Berg J: Cost effectiveness of fluvoxamine in the treatment of recurrent depression in France.

    Pharmacoeconomics 1998, 14(4):433-445.

  24. Patten SB, Lee RC: Epidemiological theory, decision theory and mental health services research.

    Soc Psychiatry Psychiatr Epidemiol 2004, 39(11):893-898.

  25. Patten SB, Lee RC: Towards a dynamic description of major depression epidemiology.

    Epidemiol Psichiatr Soc 2004, 13(1):21-28.

  26. Patten SB, Lee RC: Refining estimates of major depression incidence and episode duration in Canada using a Monte Carlo Markov model.

    Med Decis Making 2004, 24(4):351-358.

  27. Patten SB: Modelling major depression epidemiology and assessing the impact of antidepressants on population health.

    Int Rev Psychiatry 2005, 17(3):205-211.

  28. Patten SB: Markov models of major depression for linking psychiatric epidemiology to clinical practice.

    Clin Pract Epidemol Ment Health 2005, 1(1):2.

  29. Patten SB, Lee RC: Describing the longitudinal course of major depression using Markov models: data integration across three national surveys.

    Popul Health Metr 2005, 3:11.

  30. Davies R: An assessment of models of a health system.

    J Oper Res Soc 1985, 36(8):679-687.

  31. Jacobson S, Hall S, Swisher J: Discrete Event Simulation of Health Care Systems.In Delay Management in Healthcare Systems. Edited by: Hall R. Springer in Health Care Management; 2006.

  32. Law A, Kelton W: Simulation Modeling and Analysis. 3rd edition. Mc Graw Hill; 2000.

  33. Stahl JE, Rattner D, Wiklund R, Lester J, Beinfeld M, Gazelle GS: Reorganizing the system of care surrounding laparoscopic surgery: a cost-effectiveness analysis using discrete-event simulation.

    Med Decis Making 2004, 24(5):461-471.

  34. Roderick P, Davies R, Raftery J, Crabbe D, Pearce R, Patel P, et al.: Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation.

    J Med Screen 2003, 10(3):148-156.

  35. Huybrechts KF, Caro JJ, Wilson DA, O'Brien JA: Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis.

    Value Health 2005, 8(5):549-561.

  36. Zarkin GA, Dunlap LJ, Hicks KA, Mamo D: Benefits and costs of methadone treatment: results from a lifetime simulation model.

    Health Econ 2005, 14(11):1133-1150.

  37. Rauner M, Brailsford S, Flessa S: Use of discrete-event simulation to evaluate strategies for the prevention of mother-to-child transmission of HIV in developing countries.

    Journal of the Operational Research Society 2005, 56:222-233.

  38. Brown J, Karnon J, Eldabi T, Paul RJ: Using modelling in a phased approach to the economic evaluation of adjuvant therapy for early breast cancer. ABC Trial Steering Committee.

    Crit Rev Oncol Hematol 1999, 32(2):95-103.

  39. Karnon J, Brown J: Selecting a decision model for economic evaluation: a case study and review.

    Health Care Manag Sci 1998, 1(2):133-140.

  40. Ratcliffe J, Young T, Buxton M, Eldabi T, Paul R, Burroughs A, et al.: A simulation modelling approach to evaluating alternative policies for the management of the waiting list for liver transplantation.

    Health Care Manag Sci 2001, 4(2):117-124.

  41. Barton P, Bryan S, Robinson S: Modelling in the economic evaluation of health care: selecting the appropriate approach.

    J Health Serv Res Policy 2004, 9(2):110-118.

  42. Brennan A, Chick SE, Davies R: A taxonomy of model structures for economic evaluation of health technologies.

    Health Econ 2006, 15:1295-1310.

  43. Glynn P: On the role of generalized semi-Markov processes in simulation output analysis.

    Winter Simulation Conference – Proceedings of the 15th conference on Winter simulation 1983, 1:39-44.

  44. Glynn P: A GSMP formalism for discrete event systems.

    Proceedings of the IEEE 1989, 77(1):14-23.

  45. Eddy DM: Accuracy versus transparency in pharmacoeconomic modelling: finding the right balance.

    Pharmacoeconomics 2006, 24(9):837-844.

  46. Barton P, Jobanputra P, Wilson J, Bryan S, Burls A: The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.

    Health Technol Assess 2004, 8(11):1-104.

  47. Sargent R: Validation and verification of simulation models.

    Proceedings of the 2004 Winter Simulation Conference 2004.

  48. Shechter S, Schaefer A, Braithwaite R, Roberts M: Increasing the Efficiency of Monte Carlo Cohort Simulationswith Variance Reduction Techniques. Technical note.

    Medical Decision Making 2006.

  49. Christodoulou K, Vlahos K: Variable structure modelling of dynamic industry systems.

    Journal of the Operational Research Society 2000, 51:1029-1040.

  50. Roy R, Arunachalam R: Parallel discrete event simulation algorithm for manufacturing supply chains.

    Journal of the Operational Research Society 2004, 55:622-629.

  51. Davis RM: An interactive simulation in the Health Service.

    Journal of the Operational Research Society 1985, 36(7):597-606.


rating: 1.00 from 1 votes | updated on: 29 Sep 2007 | views: 958 |

share this article | email to friends

suggest a revision
print this page
print the whole article

Rate article:







excellent!bad…